Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objectives: To evaluate rotavirus (RV), diphtheria, tetanus, and acellular pertussis (DTaP), and pneumococcal conjugate vaccine (PCV) vaccine coverage and factors associated with vaccine uptake from 2018 through 2023.

Methods: We included infants born between January 1, 2018 and May 31, 2023, with a minimum of 9 months of enrollment in the first 12 months of life and at least 1 medical visit between 9 and 12 months at 1 of 8 Vaccine Safety Datalink health systems. We evaluated coverage with 2 doses of RV, DTaP, and PCV vaccines at 5 months and completion of recommended doses by 12 months. We evaluated associations of patient race, ethnicity, caregiver's primary language, Medicaid, and time period with vaccine uptake.

Results: We included 395 143 infants: 48.4% female; 14.7% non-Hispanic Asian; 5.8% non-Hispanic Black; 34.2% Hispanic; and 20.6% with Medicaid. Coverage for 2 doses of all 3 vaccines at 5 months was 87.8% (95% CI 86.9-88.7) in February 2020 vs 80.8% (95% CI 79.8-81.8) in October 2023. Vaccine series completion at 12 months was highest in January 2020 with 92.3% (95% CI 91.6-92.9) vs 89.6% (95% CI 88.8-90.3) in October 2023. Factors associated with lower vaccine uptake included having a caregiver whose primary language was not English or Spanish, non-Hispanic Black race, and Medicaid.

Conclusion: Over 3 years after the COVID-19 pandemic started, coverage for selected routine childhood immunizations remained below prepandemic levels. Demographic factors, which may reflect structural barriers to accessing care, likely affected coverage. Focused interventions are needed to improve vaccine coverage in all populations.

Download full-text PDF

Source
http://dx.doi.org/10.1542/peds.2024-068244DOI Listing

Publication Analysis

Top Keywords

routine childhood
8
vaccine
8
vaccine coverage
8
factors associated
8
vaccine uptake
8
coverage doses
8
vaccines 5 months
8
primary language
8
non-hispanic black
8
october 2023
8

Similar Publications

Objective: We sought to measure whether receipt of an enhanced 18-month well-baby visit with use of a developmental screening tool versus a routine 18-month well-baby visit (which typically involves developmental surveillance without screening) is associated with time to identification of developmental delays.

Method: We conducted a cohort study of children (17-22 months) in Ontario who received an 18-month well-baby visit (March 2020‒March 2022), followed to September 2022 using linked health administrative datasets. Visits were categorized as enhanced (n = 83,554) or routine (n = 15,723).

View Article and Find Full Text PDF

Background: This study intended to explore the levels of 25(OH)D and 25(OH)D in children with autism spectrum disorder (ASD) and analyzed the correlation between 25(OH)D, 25(OH)D levels and ASD core symptoms, children development.

Methods: A total of 208 children with ASD who were diagnosed in hospital from January 2021 to December 2023 were selected as the ASD group. 208 children for routine physical examination were selected as the control group.

View Article and Find Full Text PDF

Background: Parental vaccine hesitancy (VH) remains a public health concern in Georgia, where misinformation and distrust continue to hinder routine childhood immunization. VH is shaped by psychological, sociocultural, and informational factors, including trust in science, public authorities, and religious institutions. This study examined whether trust-related variables were stronger predictors of VH than traditional sociodemographic characteristics.

View Article and Find Full Text PDF

Introduction: Despite high coverage of routine childhood vaccines, uptake of the human papillomavirus (HPV) vaccine in the Pacific Island nation of Tonga has been slow. Culturally appropriate communication resources on the importance, safety, and effectiveness of the HPV vaccine are critical to support acceptance and uptake. To develop these resources, it is important to understand what people want to know.

View Article and Find Full Text PDF

Objective: To understand the frequency and trends in reported outcomes of safety and effectiveness for recombinant human growth hormone (rhGH) therapy for growth hormone deficiency (GHD) in childhood.

Methods: A systematic review was performed in seven English and Chinese language databases. Eligibility criteria included all studies published between 2003 and 2022, with participants who started rhGH before the age of 16 years for GHD.

View Article and Find Full Text PDF